Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$26.86 -1.64%

-$0.38 today

Market cap
$1.87B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 0.99M

Average 0.71M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$33.01M

FY 2025 · Annual

Investing Cash Flow

$26.66M

FY 2025 · Annual

-31.2% YoY

Financing Cash Flow

-$18.56M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(211.84M)124.34M(118.67M)(122.7M)(81.13M)
Depreciation & Amortization9.58M12M17.31M11.19M11.11M
Deferred Income Tax(953K)1.94M(757K)691K945K
Stock-Based Compensation10.76M4.02M8.1M17.79M28.03M
Change in Working Capital393K4.02M(25.55M)(30.95M)7.5M
Accounts Receivables(266K)(17.51M)13.92M(36.36M)51.2M
Inventory00000
Accounts Payables16.48M26.48M(44.77M)14.34M(23.65M)
Other Working Capital(15.82M)(4.96M)5.3M(8.93M)(20.05M)
Other Non-Cash Items(387K)(2.21M)1.27M13.93M532K
Operating Cash Flow(192.45M)144.11M(118.3M)(110.04M)(33.01M)
Capital Expenditures(13.29M)(13.13M)(4.08M)(3.07M)(1.52M)
Acquisitions (Net)00000
Purchases of Investments(35.08M)(40.72M)(553.25M)(283.74M)(196.06M)
Sales of Investments192.96M(40.72M)350.07M325.57M225.08M
Other Investing Activities(881K)40.72M(1.6M)(1.08M)0
Investing Cash Flow144.6M(53.85M)(207.25M)38.76M26.66M
Debt Repayment(17K)(14K)(21K)(14K)0
Common Stock Issued0107.53M76.1M023.32M
Common Stock Repurchased000(30.05M)(41.7M)
Dividends Paid00000
Other Financing Activities8.03M1.06M5.77M9.61M(181K)
Financing Cash Flow8.01M108.58M81.85M(20.45M)(18.56M)
Effect of Forex Changes(325K)203K354K286K(45K)
Net Change in Cash(40.17M)199.05M(243.36M)(91.45M)(24.95M)
Free Cash Flow(205.74M)130.98M(122.38M)(113.11M)(34.53M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$81.1M
+ D&A$11.1M
+ Stock-Based Comp$28.0M
+ Deferred Tax$945.0K
+ Working Capital$7.5M
+ Other Non-Cash$532.0K
= Operating Cash Flow-$33.0M
- Capex-$1.5M
= Free Cash Flow-$34.5M

Analysis

FY2025 free cash flow is -$34.5M. FCF conversion is 42.6% of net income. Operating cash flow was -$33.0M, with capex of -$1.5M. The largest bridge item is Stock-Based Comp at $28.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
8-K/A8-K/A filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
ARSARS filingOct 26, 2026
DEFA14ADEFA14A filingOct 26, 2026

Does ZYME generate free cash flow?

Zymeworks Inc. (ZYME) generated -$34.53M of free cash flow in fiscal 2025.

How much operating cash flow does ZYME produce?

Operating cash flow was -$33.01M, before capital expenditures of $1.52M.